Heidemarie Kletzl

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis

Scott D. Newsome, Ewa Krzystanek, Krzysztof Selmaj, Michal Dufek et autres

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis

Scott D. Newsome, Ewa Krzystanek, Krzysztof Selmaj, Michal Dufek et autres

us, pl, cz, it, ch, gb, ca (code pays fourni par la source)

Bewertung der Bioäquivalenz und des Nahrungseffekts einer neuen Tablettenformulierung von Risdiplam bei gesunden Probanden

Željko Uzelac, Heidemarie Kletzl, Katja Heinig, Birgit Jaber et autres

de, ch, gb, us (code pays fourni par la source)

Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy

Richard S. Finkel, J. W. Parker, Matthew Civitello, Alfonso Lavado et autres

us, ch (code pays fourni par la source)

178. B-cell Levels and Placental Transfer in Infants Potentially Exposed to Ocrelizumab During Pregnancy: Primary Analysis of the Prospective Multicentre, Open-label Phase IV MINORE study

Kerstin Hellwig, Riley Bove, Celia Oreja‐Guevara, Ruth Dobson et autres

de, us, es, gb, fr, it, ch (code pays fourni par la source)

175. B-cell Levels in Infants of Lactating Women with Multiple Sclerosis Receiving Ocrelizumab: SOPRANINO Primary Results

Kerstin Hellwig, Celia Oreja‐Guevara, Ruth Dobson, Sandra Vukusic et autres

de, es, gb, fr, us, it, ch (code pays fourni par la source)

Subcutaneous ocrelizumab in multiple sclerosis: results of the phase Ib dose-finding OCARINA I study

Newsome Scott, Goldstick Lawrence, Townsend Ben, Oscar Bortolami et autres

us, ch, gb (code pays fourni par la source)

Correlation of individual SMN protein with observed efficacy in the risdiplam SMA clinical trials

Heidemarie Kletzl, Cleary Yumi, G K Paul, Chiriboga Claudia A et autres

ch, gb, us, it (code pays fourni par la source)

Bioequivalence and food effect assessment for a new risdiplam tablet formulation in healthy volunteers

Yeung Winnie, Heidemarie Kletzl, Heinig Katja, Jaber Birgit et autres

gb, ch, us (code pays fourni par la source)

Subcutaneous ocrelizumab in patients with multiple sclerosis: results of the phase III OCARINA II study

Krzystanek Ewa, Selmaj Krzysztof, Figueiredo Catarina, Oscar Bortolami et autres

us, pl, ch, gb, it (code pays fourni par la source)

Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study

Scott D. Newsome, Lawrence Goldstick, Derrick Robertson, James D. Bowen et autres

us, ch, kr, gb, ca (code pays fourni par la source)

FIREFISH parts 1 and 2: 4-year efficacy and safety of risdiplam in type 1 spinal muscular atrophy

Edmar Zanoteli, Giovanni Baranello, Odile Boespflug‐Tanguy, Nicolas Deconinck et autres

br, gb, it, fr, us, be, ch, pl, au, cn (code pays fourni par la source)